SG10201502109VA - Anti-infective compounds - Google Patents
Anti-infective compoundsInfo
- Publication number
- SG10201502109VA SG10201502109VA SG10201502109VA SG10201502109VA SG10201502109VA SG 10201502109V A SG10201502109V A SG 10201502109VA SG 10201502109V A SG10201502109V A SG 10201502109VA SG 10201502109V A SG10201502109V A SG 10201502109VA SG 10201502109V A SG10201502109V A SG 10201502109VA
- Authority
- SG
- Singapore
- Prior art keywords
- infective compounds
- infective
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31511310P | 2010-03-18 | 2010-03-18 | |
US201161440937P | 2011-02-09 | 2011-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201502109VA true SG10201502109VA (en) | 2015-05-28 |
Family
ID=44021876
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012068268A SG184073A1 (en) | 2010-03-18 | 2011-03-18 | Anti-infective compounds |
SG10201502109VA SG10201502109VA (en) | 2010-03-18 | 2011-03-18 | Anti-infective compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012068268A SG184073A1 (en) | 2010-03-18 | 2011-03-18 | Anti-infective compounds |
Country Status (18)
Country | Link |
---|---|
US (1) | US8865734B2 (en) |
EP (1) | EP2547678B1 (en) |
JP (1) | JP5944837B2 (en) |
KR (1) | KR101732212B1 (en) |
CN (1) | CN102869661B (en) |
AU (1) | AU2011229423B2 (en) |
BR (1) | BR112012023576B1 (en) |
CA (1) | CA2793086C (en) |
ES (1) | ES2572387T3 (en) |
HK (1) | HK1180683A1 (en) |
IL (1) | IL221940A (en) |
MX (1) | MX345762B (en) |
NZ (1) | NZ602311A (en) |
PL (1) | PL2547678T3 (en) |
RU (1) | RU2576662C2 (en) |
SG (2) | SG184073A1 (en) |
WO (1) | WO2011113606A1 (en) |
ZA (1) | ZA201206814B (en) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102762556B (en) * | 2009-11-05 | 2017-04-26 | 圣母大学 | Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same |
WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
NZ603884A (en) | 2010-05-27 | 2014-06-27 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
WO2012045729A1 (en) * | 2010-10-05 | 2012-04-12 | Glaxo Group Limited | Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists |
KR20140093610A (en) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | Anti-inflammation compounds |
CN103608347B (en) | 2011-05-30 | 2016-04-27 | 安斯泰来制药株式会社 | Imidazopyridine |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
EA201490807A1 (en) | 2011-10-21 | 2014-07-30 | Торрент Фармасьютикалз Лимитед | NEW SUBSTITUTED IMIDAZOPIRIMIDINES AS GPBAR1 MODULATORS |
US8765959B2 (en) * | 2011-12-23 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Piperidine derivatives |
KR102178590B1 (en) * | 2012-07-18 | 2020-11-13 | 유니버시티 오브 노트르 담 듀락 | 5,5-heteroaromatic anti-infective compounds |
WO2014021383A1 (en) * | 2012-07-31 | 2014-02-06 | 協和発酵キリン株式会社 | Condensed ring heterocyclic compound |
US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9624214B2 (en) * | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
BR112015012571B1 (en) * | 2012-11-30 | 2022-05-24 | Astellas Pharma Inc | Imidazopyridine compounds and therapeutic uses thereof |
ES2946360T3 (en) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
ES2644025T3 (en) * | 2013-07-17 | 2017-11-27 | Global Alliance For Tb Drug Development | Azaindole compounds, synthesis thereof, and methods of use thereof |
SG11201600686QA (en) * | 2013-08-02 | 2016-02-26 | Pasteur Institut Korea | Anti-infective compounds |
RU2687276C2 (en) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Compounds suitable for use as atr kinase inhibitors |
PL3105218T3 (en) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
LT3105226T (en) | 2014-02-13 | 2019-11-11 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
WO2015124544A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
EP3119777A1 (en) | 2014-03-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US20170057958A1 (en) | 2014-05-02 | 2017-03-02 | Bayer Pharma Aktiengesellschaft | Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases |
CN103965193B (en) * | 2014-05-30 | 2016-04-06 | 浙江司太立制药股份有限公司 | N-(benzene oxyalkyl) imidazo [1,2-a] pyridine-3-amides and preparation method thereof |
LT3152212T (en) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016087343A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
MX2017016788A (en) * | 2015-07-02 | 2018-07-06 | Janssen Sciences Ireland Uc | Antibacterial compounds. |
SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
CA2998375A1 (en) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2018536693A (en) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 2-Phenyl-3- (piperazinomethyl) imidazo [1,2-a] pyridine derivatives as blockers of TASK-1 and TASK-2 channels for treating sleep-related breathing disorders |
JP2018538296A (en) | 2015-12-10 | 2018-12-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | Substituted perhydropyrrolo [3,4-c] pyrrole derivatives and uses thereof |
DK3394033T3 (en) | 2015-12-22 | 2021-01-04 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS |
WO2017146246A1 (en) * | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | Piperidine derivative |
PE20190377A1 (en) | 2016-04-22 | 2019-03-08 | Incyte Corp | FORMULATIONS OF AN LSD INHIBITOR 1 |
MA44860A (en) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EA201990043A1 (en) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | ANTIBACTERIAL CONNECTIONS |
JP2019518050A (en) * | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Heterocyclic compounds as antibacterial agents |
BR112018076534A2 (en) | 2016-06-20 | 2019-04-02 | Incyte Corporation | heterocyclic compounds as immunomodulators |
ES2930092T3 (en) | 2016-07-14 | 2022-12-07 | Incyte Corp | Heterocyclic compounds as immunomodulators |
JOP20190005A1 (en) | 2016-07-20 | 2019-01-20 | Bayer Ag | Substituted diazahetero-bicyclic compounds and their use |
CN106279123B (en) * | 2016-08-15 | 2018-09-04 | 郑州大学 | 3- (benzenesulfonylmethyl) imidazoheterocycles class compound and its synthetic method |
JOP20190024A1 (en) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
MA47120A (en) | 2016-12-22 | 2021-04-28 | Incyte Corp | PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
CN110831630A (en) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | Combination therapy |
WO2018184976A1 (en) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyridinecarboxamides and use of same |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
JOP20190284A1 (en) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders |
EP3428815A1 (en) | 2017-07-11 | 2019-01-16 | Institut Pasteur | Docking method based on saturation transfer difference nmr data, and means for its implementation |
EP3691619A1 (en) | 2017-10-05 | 2020-08-12 | Quretech Bio AB | Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis |
KR20200104873A (en) | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | Tubulin inhibitor |
CN108159049B (en) * | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | New application of pyridine compound |
WO2019148244A1 (en) * | 2018-02-01 | 2019-08-08 | The University Of Sydney | Anti-cancer compounds |
CN111788204B (en) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | Substituted pyrrolizine compounds as inhibitors of HBV replication |
CN112384515A (en) | 2018-02-27 | 2021-02-19 | 因赛特公司 | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors |
CR20200520A (en) | 2018-03-30 | 2021-03-09 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3790877B1 (en) | 2018-05-11 | 2023-03-01 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CN109651363B (en) * | 2019-01-03 | 2020-06-26 | 东华理工大学 | Aminomethylated imidazo [1,2-a ] pyridine compound and preparation method thereof |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
IL290047A (en) * | 2019-07-30 | 2022-07-01 | Qurient Co Ltd | Different forms of 6-chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide |
TW202115059A (en) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Salts of a pd-1/pd-l1 inhibitor |
TW202124379A (en) * | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | Benzyl amine-containing 5,6-heteroaromatic compounds useful against mycobacterial infection |
WO2021048342A1 (en) | 2019-09-13 | 2021-03-18 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
EP4038069A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
TW202126652A (en) | 2019-09-30 | 2021-07-16 | 美商英塞特公司 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
BR112022005068A2 (en) * | 2019-09-30 | 2022-09-06 | Janssen Sciences Ireland Unlimited Co | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
WO2021122996A1 (en) * | 2019-12-20 | 2021-06-24 | Qurient Co., Ltd. | A pharmaceutical oral dosage form of q203 |
JP2023517519A (en) * | 2020-03-02 | 2023-04-26 | シロナックス・リミテッド | ferroptosis inhibitor diarylamine paraacetamides |
CN111393435A (en) * | 2020-03-16 | 2020-07-10 | 青岛吉澳医药科技有限公司 | Azaindole amide compound and preparation method and application thereof |
US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
US11767319B2 (en) | 2020-07-15 | 2023-09-26 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
CA3200844A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
EP4247368A1 (en) | 2020-11-19 | 2023-09-27 | Third Harmonic Bio, Inc. | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same |
TW202237116A (en) * | 2020-12-02 | 2022-10-01 | 日商塩野義製藥股份有限公司 | A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin |
AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
US20240182495A1 (en) | 2021-03-17 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
AU2022240967A1 (en) | 2021-03-17 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
TW202325274A (en) | 2021-10-28 | 2023-07-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | Antibacterial compounds |
WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE598759A (en) * | 1960-01-04 | |||
US3133076A (en) * | 1961-04-06 | 1964-05-12 | Simes | Phenyl-imidazo(1, 2-a)pyridine-6-car-boxylic acids and their esters |
US3105834A (en) * | 1961-10-11 | 1963-10-01 | Norwich Pharma Co | 2-(5-nitro-2-furyl)-imidazo [1, 2-alpha]-pyridine or-pyrimidine |
US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
KR20020038804A (en) * | 1999-10-08 | 2002-05-23 | 파퀘스, 파우쓰-베르구스 | Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
WO2001092257A1 (en) | 2000-05-26 | 2001-12-06 | Neurogen Corporation | Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands |
DE602005015833D1 (en) * | 2004-03-19 | 2009-09-17 | Warner Lambert Co | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS |
WO2007027999A2 (en) | 2005-08-31 | 2007-03-08 | Smithkline Beecham Corporation | Chemical compounds |
WO2007034278A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Fused imidazole derivatives as c3a receptor antagonists |
WO2007034282A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
US20100298314A1 (en) * | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
CL2008001631A1 (en) * | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compounds derived from substituted heterocycles, with the presence of a phenoxy group, reverse transcriptase inhibitors; pharmaceutical composition; and use in the treatment of HIV viral infections. |
WO2009015208A1 (en) | 2007-07-23 | 2009-01-29 | Replidyne, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
US8785452B2 (en) | 2008-06-17 | 2014-07-22 | Institut National De La Sante Et De La Recherche Medicale | Anti-infective compounds |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
CN102762556B (en) * | 2009-11-05 | 2017-04-26 | 圣母大学 | Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same |
-
2011
- 2011-03-18 US US13/634,165 patent/US8865734B2/en active Active
- 2011-03-18 AU AU2011229423A patent/AU2011229423B2/en active Active
- 2011-03-18 NZ NZ602311A patent/NZ602311A/en unknown
- 2011-03-18 JP JP2012557449A patent/JP5944837B2/en active Active
- 2011-03-18 CA CA2793086A patent/CA2793086C/en active Active
- 2011-03-18 KR KR1020127027183A patent/KR101732212B1/en active IP Right Grant
- 2011-03-18 BR BR112012023576-1A patent/BR112012023576B1/en active IP Right Grant
- 2011-03-18 MX MX2012010671A patent/MX345762B/en active IP Right Grant
- 2011-03-18 CN CN201180020751.4A patent/CN102869661B/en active Active
- 2011-03-18 ES ES11711032T patent/ES2572387T3/en active Active
- 2011-03-18 SG SG2012068268A patent/SG184073A1/en unknown
- 2011-03-18 RU RU2012144317/04A patent/RU2576662C2/en active
- 2011-03-18 PL PL11711032.0T patent/PL2547678T3/en unknown
- 2011-03-18 EP EP11711032.0A patent/EP2547678B1/en active Active
- 2011-03-18 WO PCT/EP2011/001345 patent/WO2011113606A1/en active Application Filing
- 2011-03-18 SG SG10201502109VA patent/SG10201502109VA/en unknown
-
2012
- 2012-09-12 ZA ZA2012/06814A patent/ZA201206814B/en unknown
- 2012-09-13 IL IL221940A patent/IL221940A/en active IP Right Grant
-
2013
- 2013-07-09 HK HK13108001.5A patent/HK1180683A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013522253A (en) | 2013-06-13 |
CN102869661B (en) | 2015-08-05 |
RU2576662C2 (en) | 2016-03-10 |
KR101732212B1 (en) | 2017-05-02 |
ZA201206814B (en) | 2016-03-30 |
KR20130028723A (en) | 2013-03-19 |
CA2793086A1 (en) | 2011-09-22 |
AU2011229423B2 (en) | 2015-12-10 |
BR112012023576A2 (en) | 2020-09-01 |
BR112012023576B1 (en) | 2022-08-23 |
EP2547678A1 (en) | 2013-01-23 |
CA2793086C (en) | 2018-08-21 |
SG184073A1 (en) | 2012-10-30 |
NZ602311A (en) | 2014-08-29 |
ES2572387T3 (en) | 2016-05-31 |
CN102869661A (en) | 2013-01-09 |
WO2011113606A1 (en) | 2011-09-22 |
RU2012144317A (en) | 2014-04-27 |
JP5944837B2 (en) | 2016-07-05 |
WO2011113606A8 (en) | 2012-10-26 |
MX2012010671A (en) | 2013-04-03 |
HK1180683A1 (en) | 2013-10-25 |
US8865734B2 (en) | 2014-10-21 |
EP2547678B1 (en) | 2016-03-16 |
PL2547678T3 (en) | 2016-10-31 |
IL221940A (en) | 2017-03-30 |
MX345762B (en) | 2017-02-15 |
US20130065884A1 (en) | 2013-03-14 |
AU2011229423A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1180683A1 (en) | Anti-infective compounds | |
IL223783A0 (en) | Pro-neurogenic compounds | |
GB201015949D0 (en) | Compounds | |
GB201008134D0 (en) | Compounds | |
HK1187908A1 (en) | Imidazotriazinone compounds | |
GB201020179D0 (en) | New compounds | |
AP2012006641A0 (en) | New compounds | |
GB201007286D0 (en) | New compounds | |
EP2605658A4 (en) | Spiroxazolidinone compounds | |
GB201007347D0 (en) | Compounds | |
EP2649050A4 (en) | Compounds | |
GB201002563D0 (en) | Compounds | |
GB201008209D0 (en) | Compounds | |
GB201001688D0 (en) | Compounds | |
GB201002911D0 (en) | Compound | |
GB201002216D0 (en) | Compounds | |
GB201015537D0 (en) | Compounds | |
GB201008210D0 (en) | Compounds | |
GB201001796D0 (en) | Compounds | |
GB201021494D0 (en) | Compounds | |
GB201007209D0 (en) | Compound | |
GB201022042D0 (en) | Compounds | |
GB201019227D0 (en) | Compounds | |
GB201015757D0 (en) | Compounds | |
GB201015145D0 (en) | Compounds |